ArticleInvestigational new drugs2019
A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors.
Kabir Mody et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
22 papers cite it
this papercites it